tiprankstipranks
Ultragenyx Pharmaceutical (RARE)
NASDAQ:RARE
US Market
RARE
Ultragenyx Pharmaceutical
RESEARCH TOOLSreports

Ultragenyx Pharmaceutical (RARE) Income Statement

1,217 Followers

Ultragenyx Pharmaceutical Income Statement

Last quarter (Q4 2025), Ultragenyx Pharmaceutical's total revenue was $207.00M, an increase of 25.55% from the same quarter last year. In Q4, Ultragenyx Pharmaceutical's net income was $-129.00M. See Ultragenyx Pharmaceutical’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 25Dec 24Dec 23Dec 22Dec 21
Total Revenue
$ 673.00M$ 560.23M$ 434.25M$ 363.33M$ 351.41M
Gross Profit
$ 564.00M$ 483.50M$ 389.04M$ 335.01M$ 335.40M
Operating Expenses
$ 1.10B$ 1.02B$ 958.25M$ 983.93M$ 717.13M
Depreciation and Amortization
$ 35.00M$ 35.54M$ 26.01M$ 18.22M$ 13.24M
EBITDA
$ -500.00M$ -469.00M$ -516.45M$ -640.49M$ -410.32M
Operating Income
$ -535.00M$ -535.97M$ -569.21M$ -648.92M$ -381.74M
Other Income/Expenses
$ -36.00M$ -31.61M$ -39.26M$ -52.81M$ -71.24M
Pretax Income
$ -571.00M$ -567.59M$ -608.46M$ -701.73M$ -452.98M
Net Income
$ -575.00M$ -569.18M$ -606.64M$ -707.42M$ -454.02M
Per Share Metrics
Basic EPS
$ -5.83$ -6.29$ -8.25$ -10.12$ -6.70
Diluted EPS
$ -5.83$ -6.29$ -8.25$ -10.12$ -6.70
Weighted Average Shares Outstanding
 98.60M 90.54M 73.54M 69.91M 67.80M
Weighted Average Shares Outstanding (Diluted)
 98.60M 90.54M 73.54M 69.91M 67.80M
Currency in USD

Ultragenyx Pharmaceutical Earnings and Revenue History